Latest Anocca News & Updates

See the latest news and media coverage for Anocca. We track all announcements, press releases, and industry mentions in real time, all in one place.

Anocca

Biotechnology company developing precision T-cell immunotherapies

anocca.com

Headquarters: Södertälje, Sweden
Founded year: 2014
Company type: Private company
Number of employees: 100–200
Industry: Pharmaceuticals

Last updated October 1

Latest news about Anocca

In short: Anocca dosed its first patient in Sweden with ANOC-001, a KRAS-targeted TCR-T therapy for pancreatic cancer, in the VIDAR-1 trial.

Company announcements

October 1 Anocca

Anocca will dose the first patient in Sweden with TCR-T therapy

The treatment targets pancreatic cancer and is the first of its kind using gene-editing technology within the VIDAR study.

June 11 Anocca

Anocca dosed first patients with KRAS-targeted TCR-T therapy

ANOC-001 is a non-viral gene-edited therapy for pancreatic ductal adenocarcinoma, part of the VIDAR-1 clinical programme.

May 12 Anocca

Anocca publishes minutes from the 2026 annual general meeting

The minutes contain decisions from the annual general meeting and can be downloaded as a PDF.

April 14 Anocca

Anocca calls for annual general meeting on May 12, 2026

The meeting is held in Stockholm with proposals for emissions and election of board.

Media coverage

September 30 Dagens industri

Anocca will dose the first patient in Sweden with its own developed advanced TCR-T cell therapy, against pancreatic cancer

This is the first in a series of TCR-T cell therapies that are both developed and manufactured by Anocca in Södertälje. Sweden is among the first countries where...

June 11 City AM

Anocca has Dosed First Patients with Precision TCR-T Cell Therapy Targeting Mutant KRAS in Pancreatic Cancer

Anocca AB (‘Anocca’ or the ‘Company’), a clinical-stage biotechnology company developing advanced T-cell immunotherapies, ...

19 August 2025 Yahoo Finance

Anocca secures $46m to support pancreatic cancer therapy trials

Swedish biotechnology company Anocca has secured approximately Skr440m ($46m) to primarily support...

30 July 2025 Nasdaq

MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline

MaxCyte's Flow Electroporation® Technology will support non-viral gene editing in the manufacture of Anocca's TCR-T cell therapies ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) ...

Never miss news about Anocca

Track Anocca and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Anocca competitors & trending companies

Browse news for competitors to Anocca and other trending companies.